How Merck Is Trying to Keep Disrupters at Bay
Harvard Business Review
JUNE 8, 2015
EB operates Ilum as a separate business, while still drawing on Merck’s established corporate resources in IT, finance, privacy, compliance, and legal. EB plays the role of a venture capitalist or private-equity board with responsibility to sell, spin-out, or wind-down initiatives that, in practice, are found to be a poor strategic fit.
8 
Let's personalize your content